Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation - PubMed (original) (raw)
. 1998 Jul-Aug;18(4A):2317-21.
Affiliations
- PMID: 9703873
Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation
H Kanoe et al. Anticancer Res. 1998 Jul-Aug.
Abstract
Amplification of the CDK4 gene, which encodes a key molecule in the cell cycle, has been shown in some types of human neoplasms, including bone and soft tissue tumors. It is also reported that the CDK4 gene is coamplified with other sequences in the 12q13-15 region, including the MDM2 and SAS genes. Using 146 DNA samples derived from a variety of bone and soft tissue tumors, we have studied the pattern of amplification of these three genes, CDK4, MDM2, and SAS, to investigate whether there are any tumor type specific patterns of amplification. Amplification of at least one of these three genes was found in 18 tumors, and five different patterns of amplification were observed. Amplification of all of these three genes was detected in 9 cases. Amplification of the CDK4 gene without MDM2 amplification was observed in osteosarcomas and a chondrosarcoma but not in soft tissue tumors, whereas amplification of MDM2 gene alone was observed in malignant fibrous histiocytomas (MFHs), liposarcomas, and lipomas, but not in bone tumors. These results suggested that the CDK4 region is the primary target for amplification in bone tumors, whereas the MDM2 region is in soft tissue tumors. We also investigated the relationship of CDK4 amplification with retinoblastoma (RB) gene mutations in osteosarcomas, for which we have already performed the mutation analyses in detail. Interestingly, contrary to the prevailing theory that CDK4 amplification is an alternative mechanism for RB gene mutation, we found that three of four cases with amplification of the CDK4 gene showed loss of expression of the RB protein, one of which was proved to have an gross DNA alteration in the RB locus. This redundancy of mutations may indicate that the amplification of CDK4 may have some roles other than the inactivation of the RB protein in the development of osteosarcomas.
Similar articles
- MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors.
Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki MS. Nakayama T, et al. Int J Cancer. 1995 Oct 20;64(5):342-6. doi: 10.1002/ijc.2910640511. Int J Cancer. 1995. PMID: 7591308 - Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours.
Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD, Tallini G. Dei Tos AP, et al. J Pathol. 2000 Apr;190(5):531-6. doi: 10.1002/(SICI)1096-9896(200004)190:5<531::AID-PATH579>3.0.CO;2-W. J Pathol. 2000. PMID: 10727978 - Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.
Coindre JM, Hostein I, Maire G, Derré J, Guillou L, Leroux A, Ghnassia JP, Collin F, Pedeutour F, Aurias A. Coindre JM, et al. J Pathol. 2004 Jul;203(3):822-30. doi: 10.1002/path.1579. J Pathol. 2004. PMID: 15221942 - MDM2+/CDK4+/p53+ oral liposarcoma: case report and review of the literature.
Nikitakis NG, Lopes MA, Pazoki AE, Ord RA, Sauk JJ. Nikitakis NG, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):194-201. doi: 10.1067/moe.2001.116815. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001. PMID: 11505267 Review. - Osteosarcoma in blood relatives.
Longhi A, Benassi MS, Molendini L, Macchiagodena M, Picci P, Bacci G. Longhi A, et al. Oncol Rep. 2001 Jan-Feb;8(1):131-6. doi: 10.3892/or.8.1.131. Oncol Rep. 2001. PMID: 11115584 Review.
Cited by
- Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues.
Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, Conti CJ, Rodriguez-Puebla ML. Miliani de Marval PL, et al. Mol Cell Biol. 2004 Sep;24(17):7538-47. doi: 10.1128/MCB.24.17.7538-7547.2004. Mol Cell Biol. 2004. PMID: 15314163 Free PMC article. - Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation.
Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ. Rodriguez-Puebla ML, et al. Am J Pathol. 2002 Aug;161(2):405-11. doi: 10.1016/S0002-9440(10)64196-X. Am J Pathol. 2002. PMID: 12163365 Free PMC article. - High incidence of SV40-like sequences detection in tumour and peripheral blood cells of Japanese osteosarcoma patients.
Yamamoto H, Nakayama T, Murakami H, Hosaka T, Nakamata T, Tsuboyama T, Oka M, Nakamura T, Toguchida J. Yamamoto H, et al. Br J Cancer. 2000 May;82(10):1677-81. doi: 10.1054/bjoc.2000.1213. Br J Cancer. 2000. PMID: 10817503 Free PMC article. - Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
Perez M, Muñoz-Galván S, Jiménez-García MP, Marín JJ, Carnero A. Perez M, et al. Oncotarget. 2015 Dec 1;6(38):40557-74. doi: 10.18632/oncotarget.5829. Oncotarget. 2015. PMID: 26528855 Free PMC article. - Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
Lu J, Wood D, Ingley E, Koks S, Wong D. Lu J, et al. Mol Biol Rep. 2021 Apr;48(4):3637-3647. doi: 10.1007/s11033-021-06362-5. Epub 2021 Apr 24. Mol Biol Rep. 2021. PMID: 33893924 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials